On July 6, 2022 Disruptive Pharma reported the company closed a 41 million SEK financing round (Press release, Disruptive Pharma, JUL 6, 2022, View Source [SID1234649942]). We couldn’t be more excited as it allows us to fund continued development of lead pipeline project towards clinical proof-of-concept. The investment also enables Disruptive Pharma to fund continued development towards identification of a lead candidate and to complete the development of oral grade Pharma MMC. Pharmaceutical grade mesoporous magnesium carbonate, Pharma MMC, is an innovative drug delivery technology for amorphous stabilization and solubility enhancement of drug substances and for unique drug formulations. Much appreciation to our shareholders who continue to support and invest in us! We are also delighted to welcome our new shareholders who believe in our mission.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!